{"entity":{"id":"hla-loh","kind":"term","name":"HLA loss of heterozygosity","aka":[],"tldr":"Loss of an inherited HLA gene version can change which peptide-presenting molecules a tumour retains.","summary":"Human leukocyte antigen molecules normally present peptides to immune cells. HLA loss of heterozygosity concerns which inherited DNA versions remain in the sampled tumour, separately from their expression or current peptide display.","asOf":"2026-11-15","links":[{"label":"Allele-Specific HLA Loss and Immune Escape in Lung Cancer Evolution.","url":"https://pubmed.ncbi.nlm.nih.gov/29107330/"},{"label":"HGNC: HLA-A, HLA-B and HLA-C gene locations","url":"https://www.genenames.org/tools/search/#!/?query=HLA-A%20OR%20HLA-B%20OR%20HLA-C"},{"label":"Puttick et al.: genetic and non-genetic HLA disruption (2024)","url":"https://pubmed.ncbi.nlm.nih.gov/39358601/"},{"label":"Sade-Feldman et al.: B2M and antigen-presentation loss in melanoma (2017)","url":"https://pubmed.ncbi.nlm.nih.gov/29070816/"}],"tags":[],"related":["ngs","hla"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["HLA-A, HLA-B and HLA-C are on chromosome 6. HGNC places HLA-A at 6p22.1 and HLA-B and HLA-C at 6p21.33. One inherited version of each locus comes from each parent, giving up to six distinct classical class-I alleles. A segmental loss can affect several linked loci; total copy count alone does not identify which inherited versions remain.","McGranahan et al. (2017): LOHHLA found HLA LOH in 36 of 90 (40%) TRACERx non-small-cell lung cancers; it used patient-specific HLA sequences with purity and ploidy; not a prevalence for every breast cancer.","A loss may be present in one tumour population; normal and other tumour cells contribute reads; weak or indeterminate calls are not proof of retention; one region does not map every lesion.","DNA loss, reduced allele-specific RNA, reduced surface protein and B2M functional loss are separate findings; B2M loss affects many alleles at once. In a fictional comparison, the placeholder HLA-A versions A1 and A2 can have A1 lost, both retained with reduced expression, or both retained with impaired B2M support. A1 and A2 do not name specific clinical alleles. None of those DNA descriptions supplies a surface-molecule count; current display needs separate measurement.","A credible loss call asks which proposed targets depend on the lost allele and what supports presentation through retained alleles; it does not show all targets fail.","Fictional teaching exercise: Loss of a maternal haplotype carrying A*X, B*Y, C*Z challenges peptides predicted for A*X and for B*Y; retention of paternal alleles does not itself prove display.","Retain tumour/normal material, typing, named HLA alleles, usable reads, inferred allele copies, confidence, caller version and region sampled. DNA extraction uses material; computational reanalysis does not. Incorrect typing, difficult mapping and low tumour content can obscure loss. Coverage and statistical rules require workflow validation; neither a negative call nor retained DNA proves current display.","The LOHHLA PCR validation selected 82 regions from 27 tumours predicted to have either all three loci affected by LOH or none. This selection does not establish how often a typical tumour region loses all three loci. The 36-of-90 result describes the separate NSCLC cohort analysis."],"category":"Genomics & genetics"},"route":"/terms/hla-loh/","neighbours":{"term":[{"id":"hla","kind":"term","name":"HLA (human leukocyte antigen) and MHC","route":"/terms/hla/"},{"id":"neoantigen-candidate-selection","kind":"term","name":"Neoantigen candidate selection","route":"/terms/neoantigen-candidate-selection/"},{"id":"ngs","kind":"term","name":"Next-generation sequencing (NGS)","route":"/terms/ngs/"}]}}